上海润石医药科技

Runshi Pharma is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company leverages its deep expertise in medicinal chemistry to design highly selective molecules that target validated biological pathways with improved therapeutic windows. Its lead candidate, RS1805, is a potent RORγt inverse agonist currently undergoing Phase 2 clinical trials for the treatment of psoriasis. Runshi Pharma's pipeline also includes RS1802, a selective JAK1 inhibitor, and several other programs in the early clinical and preclinical stages. The company is supported by a consortium of leading life science investors and operates out of the Zhangjiang Hi-Tech Park.